Like most new cancer therapies, this will surely get “expedited” status from the US FDA, which will enable as fast a development as imaginable, like FIM (first

Like most new cancer therapies, this will surely get “expedited” status from the US FDA, which will enable as fast a development as imaginable, like FIM (first in man) within the year. If it delivers on its promise, it will receive initial approval for those with advanced metastases of the initially targeted forms of cancer within a year after that. A major question is the cost of the therapy. If it equals CAR-T, which it closely resembles, it will NOT see rapid adoption until the price per treatment falls below CAR-T's current bill of $500,000 US.